Latest News - Page 2 of 46 - Oklahoma Society of Clinical Oncology

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

On 8/20/21 Bristol Myers Squibb announced that Opdivo®(nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior […]

Read More

Permanent J-Code Assigned for Pepaxto® (melphalan flufenamide)

INDICATION:   PEPAXTO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication is approved under […]

Read More

Clinical Trial Support Center Available to Connect Patients with Blood Cancer to Clinical Trials

ASH and The Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center (CTSC) have collaborated to enhance access to LLS’s free service providing clinical trials navigation and support to health care professionals, and patients with blood cancer and their families. ASH member physicians and their care teams, along with patients and caregivers, receive one-on-one support […]

Read More

KEYTRUDA® receives additional FDA approval

The FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Recommended Dosage for High-Risk Early-Stage TNBC Please refer to the Prescribing Information for KEYTRUDA for information […]

Read More

New ASCO-COA Oncology Medical Home Standards Set High Bar, Offers Roadmap for Comprehensive High-Quality, Patient-Centered Cancer Care Delivery 

On July 13, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards to provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence based cancer care. By releasing the new standards, ASCO and COA seek to achieve a broad consensus among all […]

Read More

Oncopeptides announces that PEPAXTO® is now included in the NCCN Clinical Practice Guidelines.

Melphalan Flufenamide (PEPAXTO®) is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 6.2021 – April 12, 2021 Category 2A1 Definitions for National Comprehensive Cancer Network® (NCCN®) Categories:   Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.   For more […]

Read More

OSCO and ASCO Supported Co-Pay Accumulator Ban Bill Signed into Law

On April 19, Oklahoma Governor Kevin Stitt (R) signed co-pay accumulator ban bill HB 2678 into law. This measure requires Pharmacy Benefit Managers (PBMs) to include any amount paid by an enrollee, or on behalf of an enrollee, when calculating the enrollee’s out of pocket maximum, copay, coinsurance, deductible, or cost sharing requirement. The Oklahoma […]

Read More

Natera announces allocation of $1,000,000 to Signatera Research Fund for initiatives that focus on using Signatera to develop or refine specific and defined medical knowledge.

Signatera Research Fund Natera supports independent research and education initiatives from the global healthcare community that align with Natera’s medical and scientific strategy for improving patient outcomes in areas of unmet medical need. This year, Natera has allocated $1,000,000 for research initiatives that are focused on using Signatera to develop or refine specific and defined […]

Read More

FDA approves KEYTRUDA® (pembrolizumab) for additional treatment.

Merck has announced that the FDA has approved KEYTRUDA® (pembrolizumab) for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. PD-L1 diagnostic testing is […]

Read More

Oncopeptides offers new FDA Approved Treatment Option for Some Patients with Triple-Class Refractory Multiple Myeloma

Oncopeptides will host a seminar to explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Join OncLive® and Oncopeptides, along with experts […]

Read More